2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

By P. Ponikowski, A. Voors, S. Anker, Héctor Bueno, J. Cleland, Andrew J.S. Coats, Volkmar Falk, J. González-Juanatey, V. Harjola, E. Jankowska and 11 more. Revista Española de Cardiología, 2016

3,884 citations recorded by the source corpus.

Authors/Task Force Members: Piotr Ponikowski* (Chairperson) (Poland), Adriaan A. Voors* (Co-Chairperson) (The Netherlands), Stefan D. Anker (Germany), Héctor Bueno (Spain), John G. F. Cleland (UK), Andrew J. S. Coats (UK), Volkmar Falk (Germany), José Ramón González-Juanatey (Spain), Veli-Pekka Harjola (Finland), Ewa A. Jankowska (Poland), Mariell Jessup (USA), Cecilia Linde (Sweden), Petros Nihoyannopoulos (UK), John T. Parissis (Greece), Burkert Pieske (Germany), Jillian P. Riley (UK), Giuseppe M. C. Rosano (UK/Italy), Luis M. Ruilope (Spain), Frank Ruschitzka (Switzerland), Frans H. Rutten (The Netherlands), Peter van der Meer (The Netherlands)

Subfields: Cardiology and Cardiovascular Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/00cfa6445d5ba9777405c4cfd33f91f9d166b02e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. W. Paulus
2. J. Herrmann
3. Gerasimos Filippatos
4. Jose Luis Zamorano
5. F. Cosentino
6. C. Tschöpe
7. D. Lenihan
8. P. Lancellotti

In Radiology, Nuclear Medicine and Imaging

1. J. Herrmann
2. W. Paulus
3. F. Cosentino
4. C. Tschöpe

Citations in the corpus

• Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology (2018, positive): “8%, HFpEF and HFrEF, respectively) based on the ESC diagnostic criteria (77, 78).”
• Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations (2020, positive): “Symptomatic patients with significant reduction in LVEF are classified as stage C HF (structural heart disease with prior or current symptoms of HF) and should be treated with HF-specific medications in accordance with clinical practice guidelines.(167,168) In many instances, standard cardiac-based ”